Maine Medicine Weekly Update - Maine Medicine Weekly Update: 12/24/2021
(Print All Articles)

Enjoy The Holidays, Our Weekly Newsletter & Thank You For All You Do

Illustration 48005353 / Doctor Christmas Skypixel | Dreamstime.com

The Maine Medical Association Board of Directors and staff wishes the Happiest of Holidays to all of you and we thank you for your membership and dedication to caring for your neighbors.

It is your empathy and high standard for giving high quality care day in and day out that makes you special.

Thank you for all you do and for being an integral part of medicine in Maine. 

There is no question Mainers appreciate your care and the Maine Medical Association greatly values your membership.

The Maine Medical Association Board of Directors and staff wishes the Happiest of Holidays to all of you and we thank you for your membership and dedication to caring for your neighbors.

It is your empathy and high standard for giving high quality care day in and day out that makes you special.

Thank you for all you do and for being an integral part of medicine in Maine. 

There is no question Mainers appreciate your care and the Maine Medical Association greatly values your membership.


 

FDA Updates: Pfizer & Merck Oral Antivirals Authorized; Omicron & Monoclonal Antibodies

The FDA authorized two oral antivirals for the treatment of COVID-19 in certain patients. Pfizer’s Paxlovid – authorized for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients 12 and older, and Merck’s molnupiravir – authorized for the treatment of mild-to-moderate COVID-19 in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19.

Paxlovid is the first oral, at-home treatment to be authorized by the agency

The FDA authorized two oral antivirals for the treatment of COVID-19 in certain patients. Pfizer’s Paxlovid – authorized for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients 12 and older, and Merck’s molnupiravir – authorized for the treatment of mild-to-moderate COVID-19 in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19.

Paxlovid is the first oral, at-home treatment to be authorized by the agency

The FDA released a joint statement on the circulating SARS-CoV-2 viral variants, including Omicron, and how the variants may be associated with resistance to monoclonal antibodies.

The FDA has updated the SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests web page to share new information regarding:

·       Background information on the SARS-CoV-2 omicron variant

·       Impact of the SARS-CoV-2 omicron variant on antigen diagnostic tests

The update revised:

·       The FDA’s recommendations for clinical laboratory staff and health care providers.

·       Information on the impact of the SARS-CoV-2 omicron variant on molecular diagnostic tests.

The FDA continues to monitor and evaluate the impact of genetic variants on antigen tests and released further information on the Omicron variant and its impact on antigen diagnostic tests

Deeper Dive

The FDA authorized two oral antivirals for the treatment of COVID-19 in certain patients. Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) is authorized for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms or about 88 pounds) with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Merck’s molnupiravir is authorized for the treatment of mild-to-moderate COVID-19 in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate. Both treatments are available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset.

The FDA released a joint statement on the circulating SARS-CoV-2 viral variants, including Omicron, and how the variants may be associated with resistance to monoclonal antibodies. Data show that it is unlikely that bamlanivimab and etesevimab administered together or REGEN-COV will retain activity against this variant. Based on similar cell culture data currently available, sotrovimab appears to retain activity against the Omicron variant. FDA updated the Health Care Provider Fact Sheets for bamlanivimab and etesevimab administered togetherREGEN-COV, and sotrovimab with specific information regarding expected activity against the Omicron variant (B.1.1.529/BA.1). Based on this information, ASPR will pause any further allocations of bamlanivimab and etesevimab together, etesevimab alone, and REGEN-COV pending updated data from the CDC. Shipments of sotrovimab did resume this week, and delivery of 55,000 doses of product has begun. An additional 300,000 doses of sotrovimab will be available for distribution in January. As additional data become available, FDA and ASPR will provide updates and further recommendations and consider if additional actions are warranted.

The FDA is collaborating with the National Institutes of Health’s (NIH) RADx program to study the performance of antigen tests with patient samples that have the omicron variant. Our RADx partners are currently evaluating the performance of antigen tests with patient samples containing live virus, which is the best way to evaluate true test performance.

Omicron Variant: Impact on Antigen Diagnostic Tests (As of 12/22/2021)

Resources:

  • FDA’s Coronavirus Disease 2019 (COVID-19) webpage

Maine CDC Updates & Guidance

The Maine CDC has transitioned to Pfizer’s gray cap formulation for adults and adolescents (gray cap) as of Friday, December 24.

The CDC has also shut off ordering the Johnson & Johnson COVID-19 vaccine through ImmPact.

The Maine CDC has transitioned to Pfizer’s gray cap formulation for adults and adolescents (gray cap) as of Friday, December 24.

The CDC has also shut off ordering the Johnson & Johnson COVID-19 vaccine through ImmPact.

They have closed for the 1170 dose Pfizer presentation (purple cap) and transitioning to the new presentation (gray cap) with a 300 minimum dose quantity.

Download the Maine CDC memo on Pfizer’s Gray Cap Formulation and Johnson & Johnson Updates

J&J COVID-19 Vaccine Updates

On Thursday, December 16, the U.S. CDC endorsed updated recommendations made by the Advisory Committee on Immunization Practices (ACIP) for the prevention of COVID-19,expressing a clinical preference for individuals to receive an mRNA COVID-19 vaccine overJohnson & Johnson.

To utilize current inventory levels across Maine, we will be shutting off ordering for the Johnson & Johnson COVID-19 vaccine in ImmPact. This change will be effective Friday,

December 24. For providers who choose to continue vaccinating with the Johnson & Johnson COVID-19 vaccine, an allocation request may be submitted to:

C19Allocations.MeCDC@maine.gov

Please contact the Maine Immunization Program with any questions at 207-287-3746 or

ImmunizeME.DHHS@maine.gov

Reminder: Everyone Ages 16 and Older Can Get a Booster Shot

The US CDC has updated its recommendations for COVID-19 vaccines with a preference for people to receive an mRNA COVID-19 vaccine (Pfizer-BioNTech and Moderna).

 

The US CDC has updated its recommendations for COVID-19 vaccines with a preference for people to receive an mRNA COVID-19 vaccine (Pfizer-BioNTech and Moderna).

Read CDC’s media statement.

US CDC COVID-19 Vaccine Booster Shots webpage.

 


US CDC Reduces Time for Health Care Workers to Isolate & Updates School Guidelines

The US CDC has updated rules for health care workers who test positive for COVID, reducing the required isolation time to combat fears of staffing shortages.

CDC Director Rochelle Walensky announced new, updated COVID-19 school guidelines on testing and quarantining for Covid-19

 

The US CDC has updated rules for health care workers who test positive for COVID, reducing the required isolation time to combat fears of staffing shortages.

CDC Director Rochelle Walensky announced new, updated COVID-19 school guidelines on testing and quarantining for Covid-19

The US CDC has updated rules for health care workers who test positive for COVID, reducing the required isolation time to combat fears of staffing shortages.—Newsweek

 

Key Points

In general, asymptomatic HCP who have had a higher-risk exposure do not require work restriction if they have received all COVID-19 vaccine doses, including booster dose, as recommended by CDC and do not develop symptoms or test positive for SARS-CoV-2. The duration of protection offered by booster doses of vaccine and their effect on emerging variants are not clear; additional updates will be provided as more information becomes available.

US CDC webpage: Interim Guidance for Managing Healthcare Personnel with SARS-CoV-2 Infection or Exposure to SARS-CoV-2

US CDC School Guidelines for Student Exposure

The guidelines will now allow for a student that has been exposed to COVID-19 to avoid quarantine, if they and the person they were exposed to wore a mask during the time of exposure. If the student continues to test negative 7 days after exposure, they can resume classes without the need to quarantine. The students are expected to continue to get tested up until 7 days after exposure and remain masked while indoors. – Washington Post

English Study: Booster Shots Protect Against Omicron for About 10 Weeks

As US health officials announced the Omicron wave (which has not peaked) has officially surpassed the height of the Delta surge, a new study from the UK Health Security Agency shows, “Booster protection against symptomatic illness caused by the Omicron variant dropped by up to 25% within 10 weeks, new real-world data found — though it's not yet clear whether everyone may need further doses in 2022.”

As US health officials announced the Omicron wave (which has not peaked) has officially surpassed the height of the Delta surge, a new study from the UK Health Security Agency shows, “Booster protection against symptomatic illness caused by the Omicron variant dropped by up to 25% within 10 weeks, new real-world data found — though it's not yet clear whether everyone may need further doses in 2022.”

Booster protection against symptomatic COVID-19 caused by Omicron lasts about 10 weeks, data shows. It may mean fourth doses in 2022 — depending on whether protection holds against severe COVID-19. Immunocompromised Americans can already get an extra shot.

According to the UK Health Security Agency, “Booster protection against symptomatic illness caused by the Omicron variant dropped by up to 25% within 10 weeks, new real-world data found — though it's not yet clear whether everyone may need further doses in 2022.”

Business Insider: Booster Shots Protect Against Symptomatic Omicron Infection for About 10 Weeks, Study Finds — Which Could Mean More Doses For Some In 2022

UK Health Security Agency technical briefing: SARS-CoV-2 Variants Of Concern And Variants Under Investigation In England

Patients Vaccinated for COVID-19 Have Shorter Hospital Stays Than Unvaccinated Patients

Average length of stay for patients hospitalized with COVID-19 shorter for vaccinated patients than unvaccinated patients – Study posted, December 21, 2021.


Average length of stay for patients hospitalized with COVID-19 shorter for vaccinated patients than unvaccinated patients – Study posted, December 21, 2021.

From epicresearch.org, Since the beginning of the COVID-19 pandemic, hospital capacity has been a consistent concern. People who are fully vaccinated against COVID-19 have a significantly reduced risk of severe illness resulting in hospitalization,1,2 which can help reduce the impact of COVID-19 on hospital capacity. We looked at how being vaccinated against COVID-19 impacts length of stay for COVID-related hospitalizations.

Adults hospitalized with COVID-19 who were fully vaccinated had shorter average hospital stays than those who were not fully vaccinated within the same age group. For example, among patients age 65 and older, the median COVID-19 hospital stay was 1.1 days shorter for those who were fully vaccinated (5.6 days) than for those not fully vaccinated (6.7 days).

epicresearch.org – Patients Vaccinated for COVID-19 Have Shorter Hospital Stays Than Unvaccinated Patients

Visit the KFF-Peterson Health System Tracker on COVID-19 breakthrough hospitalizations for more information.

 

JAMA Internal Medicine - Illness Severity With SARS-CoV-2 Infection, Delta vs Beta Variant

Question:  Do patients infected with the SARS-CoV-2 Delta variant experience more severe disease outcomes compared with those infected with the Beta variant?

Findings:  In this cohort study of 1427 persons infected with the Delta variant and 5353 persons infected with the Beta variant in Qatar, among 451 propensity score–matched pairs identified, persons infected with the Delta variant were more likely to be hospitalized (27.3% vs 20.0%) or to experience more severe disease outcomes. Infection with the Delta variant was independently associated with higher odds of experiencing any adverse outcome, and vaccination was associated with significantly reduced odds of severe disease outcomes.

Meaning:  In this cohort study, infection with the Delta variant was more severe than infection with the Beta variant in persons in Qatar, although vaccination was highly protective against severe outcomes for both variants.

Question:  Do patients infected with the SARS-CoV-2 Delta variant experience more severe disease outcomes compared with those infected with the Beta variant?

Findings:  In this cohort study of 1427 persons infected with the Delta variant and 5353 persons infected with the Beta variant in Qatar, among 451 propensity score–matched pairs identified, persons infected with the Delta variant were more likely to be hospitalized (27.3% vs 20.0%) or to experience more severe disease outcomes. Infection with the Delta variant was independently associated with higher odds of experiencing any adverse outcome, and vaccination was associated with significantly reduced odds of severe disease outcomes.

Meaning:  In this cohort study, infection with the Delta variant was more severe than infection with the Beta variant in persons in Qatar, although vaccination was highly protective against severe outcomes for both variants.

Online: Severity of Illness in Persons Infected With the SARS-CoV-2 Delta Variant vs Beta Variant in Qatar

 

US Supreme Court to Take Up Federal COVID-19 Vaccine Rules

The United States Supreme Court will oral arguments on President Biden’s COVID-19 vaccination rules for private employers and health care workers on Jan. 7.

The Court announced it would hear oral arguments on over President Biden's vaccine-or-test mandate for large employers and a regulation from the Centers for Medicare and Medicaid Services (CMS) requiring vaccines for health care workers.

The United States Supreme Court will oral arguments on President Biden’s COVID-19 vaccination rules for private employers and health care workers on Jan. 7.

The Court announced it would hear oral arguments over President Biden's vaccine-or-test mandate for large employers and a regulation from the Centers for Medicare and Medicaid Services (CMS) requiring vaccines for health care workers.

The Occupational Safety and Health Administration (OSHA) issued a rule last month requiring companies with more than 100 employees to mandate that their workers either receive a COVID-19 vaccine or undergo regular testing.

The CMS rule requires health care workers in facilities that receive Medicare and Medicaid funding – to be vaccinated. – THIS DOES NOT INCLUDE INDEPENDENT PHYSICIAN PRACTICES.

The federal rules are apart and separate from vaccine rules implemented by the State of Maine requiring health care workers to be vaccinated or receive a medical exemption. Independent physician practices are also not included under Maine’s rules.

Read more on the upcoming US Supreme Court arguments fromHealthcare Dive.

CDC: Physicians Should Discuss Meds to Reduce HIV Risk

The CDC has recommended that primary care physicians talk to all sexually active patients about prophylactic medications that can lessen HIV transmission risk. Pre-exposure prophylaxis, or PrEP, can be 99% effective in reducing risk.

The CDC has recommended that primary care physicians talk to all sexually active patients about prophylactic medications that can lessen HIV transmission risk. Pre-exposure prophylaxis, or PrEP, can be 99% effective in reducing risk.

Key Takeaways

The Centers for Disease Control and Prevention (CDC) is now recommending that physicians discuss prophylactic drugs that reduce the risk of HIV transmission (PrEP) with all of their patients who are sexually active.  

A brief discussion of a patient’s sexual history should be part of primary care and should guide physicians in discussing whether patients might need PrEP.

Many physicians skip taking a sexual history of patients—either because of their own or their patients’ discomfort. As a result, patients who could benefit from PrEP miss out on key HIV prevention measures.

verywellhealth.com – CDC: All Sexually Active Patients Should Know About HIV Prevention Drugs

US CDC – Pre-Exposure Prophylaxis (PrEP), Quick Guide: 2021 PrEP Update, Clinicians’ Quick Guide

HHS: $48 Million Available to Increase the Public Health Workforce in Rural and Tribal Communities

The U.S. Department of Health and Human Services (HHS), through the Health Resources and Services Administration’s (HRSA) Federal Office of Rural Health Policy, is announcing the availability of nearly $48 million in American Rescue Plan funding for community-based organizations to expand public health capacity in rural and tribal communities through health care job development, training, and placement. Awardees will be able to use this funding to address workforce needs related to the long-term effects of COVID-19 as well as health information technology (IT) needs and other key workforce issues.

 

The U.S. Department of Health and Human Services (HHS), through the Health Resources and Services Administration’s (HRSA) Federal Office of Rural Health Policy, is announcing the availability of nearly $48 million in American Rescue Plan funding for community-based organizations to expand public health capacity in rural and tribal communities through health care job development, training, and placement. Awardees will be able to use this funding to address workforce needs related to the long-term effects of COVID-19 as well as health information technology (IT) needs and other key workforce issues.

This notice of funding opportunity builds on the Biden-Harris Administration’s recent historic workforce announcement of awarding the largest field strength in history for its health workforce loan repayment and scholarship programs.

“The COVID-19 pandemic has reinforced the importance of a robust public health workforce to keep Americans safe and healthy, especially in communities that have experienced long-standing health disparities,” said Health and Human Services Secretary Xavier Becerra. “This investment is part of our ongoing efforts to address health workforce needs in rural and underserved communities. As we build a healthier nation, we will continue to promote health equity and strengthen rural health.”

Applicants can begin the application process on Grants.gov and apply by Friday, March 18, 2022 at 11:59 p.m. ET.

For more information, please see the materials below:

MaineCare: Payment Cycle Reminder: Christmas and New Year's Day Holidays

Payment Cycle for the Week of the Christmas Holiday

The claim payment cycle for the week of December 19, 2021 will be as follows due to the Christmas holiday:

            Payments received via EFT will be available between Thursday, 12/23 and Monday, 12/27 depending on your bank.

            Remittance Advice PDFs and 835s will be available on the Health PAS Online Portal for download on 12/23.

            Checks and paper Remittance Advices will be mailed by 12/27.

            Providers may continue to submit claims through 7:00 AM on 12/24 to be included in the following week’s payment cycle.

Payment Cycle for the Week of the New Year's Day Holiday

The claim payment cycle for the week of December 26, 2021 will be as follows due to the New Year’s Day holiday:

            Payments received via EFT will be available between Thursday, 12/30 and Monday 1/3 depending on your bank.

            Remittance Advice PDFs and 835s will be available on the Health PAS Online Portal for download on 12/30.

            Checks and paper Remittance Advices will be mailed by 1/3.

            Providers may continue to submit claims through 7:00 AM on 12/31 to be included in the following week’s payment cycle.

Medicine in the Media

The Maine Medical Association and the MMA’s Public Health Committee released a statement this week urging Mainers to vaccinate and mask during the holidays while also pleading with Maine businesses to reinstitute masking requirements and provide masks to customers who have none.

The Maine Medical Association and the MMA’s Public Health Committee released a statement this week urging Mainers to vaccinate and mask during the holidays while also pleading with Maine businesses to reinstitute masking requirements and provide masks to customers who have none.

The MMA’s full statement can be found here:

Maine Physicians – Masks & Vaccinations More Important Than Ever

Maine Public – Maine Physicians Call on Businesses To Reimpose Mask Requirements

WMTW-8 – Maine ER Doctor Says Physicians Are ‘Tired and Discouraged’ Following ICU record

Portland Press Herald – How Maine Lost Control Of Coronavirus And Became A National Hot Spot

What else we’re reading:

WGME-13 – Maine Officials Address New COVID Pill, Effectiveness of Vaccines Amid Omicron Concerns

Spectrum News – Maine Offers Mental Health Resources to Cope With Pandemic

Business Insider – ER Doctors Say This COVID-19 Wave Is Forcing Them to Deny Treatment To Other Patients Who Can Die As A Result

Washington Post – In Highly Vaccinated New England, Hospitals Are Under Unprecedented Strain as Coronavirus Surges

Washington Post – Vaccine Misinformation Has Run Rampant on Pregnancy Apps

Washington Post – South Africa’s Omicron Wave Appears to Be Falling Sharply

Walgreens Pharmacy Hours Change: Call Ahead Before Picking Up Your Medication

According to a MaineCare bulletin, Walgreens has cut back their pharmacy hours at some of their locations. This may make it difficult for your patients to get medications filled by the pharmacy. Their Walgreens pharmacy may be closed on one or both weekend days.

According to a MaineCare bulletin, Walgreens has cut back their pharmacy hours at some of their locations. This may make it difficult for your patients to get medications filled by the pharmacy. Their Walgreens pharmacy may be closed on one or both weekend days.

Patients may need to call the pharmacy before going into the store to make sure it is open. Locate store hours and store phone numbers on Walgreen's website.

OPTIONS:

If they cannot pick up your medication because the store is closed, they can do the following to get your medication:

           If the prescription has refills, please go to the nearest open pharmacy that takes MaineCare and request the pharmacist to fill a prescription for medication. The pharmacist will call Change Healthcare for an ‘early refill’ override. 

           If the prescription does not have refills, they must call their physician and ask for a new prescription. The prescriber will call the prescription into the nearest pharmacy that takes MaineCare. The pharmacist will call Change Healthcare for an ‘early refill’ override. 

Patients must bring MaineCare card or MaineCare ID when picking up medication.

If you have questions, please MaineCare's Pharmacy Help Desk at 1-866-796-2463. We are open Monday through Friday, 8:00 am to 5:00 pm. 

Maine Medical Education Trust (MMET) CME Program Coordinator

The Maine Medical Association (MMA) and Maine Medical Education Trust (MMET) CME Program Coordinator is one position with two separate functions.  This individual will learn the national system of regulation and oversight of providers of continuing medical education for allopathic physicians (M.D.s) through the Accreditation Council on Continuing Medical Education (ACCME).  This role is both administrative and managerial, and it requires a highly motivated self-starter who can learn an increasingly complex accreditation process and stay current as the system is rapidly changing.  This individual will be the sole staff member responsible for the statewide CME provider accreditation function of the Maine Medical Association, the Maine Medical Education Trust as one of those accredited CME providers, and the MMA’s Continuing Medical Education Accreditation Committee. This individual will assist in the planning, implementation, and evaluation of CME activities in the State of Maine. This individual will work closely with the staff of the ACCME based in Chicago, IL and will also be MMA’s liaison with the staff members performing similar work at the New Hampshire Medical Society and Massachusetts Medical Society.

The Maine Medical Association (MMA) and Maine Medical Education Trust (MMET) CME Program Coordinator is one position with two separate functions. This individual will learn the national system of regulation and oversight of providers of continuing medical education for allopathic physicians (M.D.s)  through the Accreditation Council on Continuing Medical Education (ACCME).  This role is both administrative and managerial, and it requires a highly motivated self-starter who can learn an increasingly complex accreditation process and stay current as the system is rapidly changing.  This individual will be the sole staff member responsible for the statewide CME provider accreditation function of the Maine Medical Association, the Maine Medical Education Trust as one of those accredited CME providers, and the MMA’s Continuing Medical Education Accreditation Committee. This individual will assist in the planning, implementation, and evaluation of CME activities in the State of Maine. This individual will work closely with the staff of the ACCME based in Chicago, IL and will also be MMA’s liaison with the staff members performing similar work at the New Hampshire Medical Society and Massachusetts Medical Society.

ESSENTIAL FUNCTIONS AND PERFORMANCE EXPECTATIONS:

CME Program Coordinator, MMA and MMET

MMA Functions:

  • CME Program Coordinator - Oversee 17 providers and maintain all records in accordance with the ACCME Guidelines
  • Participate in ACCME Academy classes as required
  • Maintain ACCME PARS (Program and Activity  Reporting System) Database of all providers in the State of Maine
  • Attend ACCME required meetings (April and May in Chicago)
  • Ensure that CME information on MMA web site is current
  • Meeting management for Annual CME Dinner Meeting activity (1 per year)
  • Responsible for learning the Element and Essential Criteria of ACCME along with the Markers of Equivalency
  • Communicate regularly with staff counterparts at CME Provider entities
  • Attend site surveys as a surveyor and with surveyors

·      Manage correspondence with CME providers including notifications of re-accreditation and for annual reporting requirements

·      Quarterly CCMEA Committee meeting coordination: preparing meeting agendas and keeping minutes

·      Development of CME Program (innovative ideas and initiatives)

·      Leads recruitment and retention of CME providers

·      Leads recruitment and retention of CCMEA Committee members and surveyors

MMET Functions:

  • Ensures approval of MMA CME activities through the MMET
  • Directs invoicing and collections of CME program activity approval fees
  • Provide on-site support (when applicable) for programs including attendance, the distribution and collection of evaluation feedback, faculty disclosure and commercial support acknowledgement 
  • Develop and maintain a file for each program offered during the current accreditation term (Physician attendance records must be kept for a minimum of 6 years)
  • Assist with the CCMEA re-accreditation process; complete the application, review program files, work with MMA staff to establish a survey date, and attend the re-accreditation survey         
  • Attend the annual CCMEA Medical Education Conference and other educational opportunities regionally or nationally    

·      Responsible for ensuring that CME activities meet the requirements of the ACCME Criteria

·      Maintain ACCME PARS Database of all MMET approved activities

·      Maintain the MMET Pilot Program Oversight and Review

·      Responsible for MMA site survey materials for Accreditation

 

MINIMUM KNOWLEDGE,SKILLS, AND ABILITIES REQUIRED

  • Bachelor’s degree or five years related experience or equivalent combination of education and experience
  • Ability to work both independently and as part of a team
  • Strong skills in multiple Windows-based, including Microsoft Word, Microsoft Excel, Microsoft PowerPoint, as well as experience in learning new software programs
  • Analytic ability and effective negotiation skills
  • Excellent interpersonal, written, and oral communication, time management, and customer service skills
  • Ability to establish priorities, adapt to shifting priorities, and handle time-sensitive projects with multiple deadlines under pressure
  • Ability to think creatively, solve problems, take initiative, use good judgment, and make sound decisions
  • Ability to serve as a proactive resource to internal and external constituents and to identify appropriate resources to ensure that organizational, departmental, and external needs are met with diplomacy and tactfulness

·       Ability to learn ACCME and AMA accreditation requirements

  • Some travel and work after regular business hours is required
  • Valid Maine Driver’s License and reliable transportation

Physical Demands: Ability to write, operate acomputer, printer, faxmachine, photocopier, and use